

**Amendments to the Claims**

Please cancel Claims 11, 15, 18 and 21.

Please amend Claims 1, 3-5, 7-8 and 14.

Please add new Claim 22.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A method of treating a TNF $\alpha$ -mediated ~~myelodysplastic syndrome~~ neoplastic disease in a human comprising administering to the human an effective TNF $\alpha$ -inhibiting amount of an anti-TNF $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNF $\alpha$  antibody or antigen-binding fragment thereof (i) competitively inhibits binding of human TNF $\alpha$  to anti-TNF $\alpha$  chimeric monoclonal antibody cA2 which comprises the variable region of monoclonal antibody A2 (ATCC Accession No. PTA-7045) and (ii) binds to a neutralizing epitope of human TNF $\alpha$  *in vivo* with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant ( $K_a$ ), as determined by Scatchard analysis.
2. (Canceled).
3. (Currently Amended) A method of treating a TNF $\alpha$ -mediated ~~myelodysplastic syndrome~~ neoplastic disease in a human comprising administering to the human an effective TNF $\alpha$ -inhibiting amount of anti-TNF $\alpha$  chimeric monoclonal antibody cA2 which comprises the variable region of monoclonal antibody A2 (ATCC Accession No. PTA-7045).
4. (Currently Amended) A method for treating a TNF $\alpha$ -mediated ~~myelodysplastic syndrome~~ neoplastic disease in a human comprising administering to the human at least one anti-TNF $\alpha$  chimeric monoclonal antibody cA2 which comprises the variable region of

monoclonal antibody A2 (ATCC Accession No. PTA-7045), or an antigen-binding fragment thereof.

5. (Currently Amended) A method of treating a TNF $\alpha$ -mediated ~~myelodysplastic syndrome~~ neoplastic disease in a human comprising administering to the human an effective TNF $\alpha$ -inhibiting amount of an anti-TNF $\alpha$  ~~chimeric~~ antibody or antigen-binding fragment thereof, wherein said anti-TNF $\alpha$  ~~chimeric~~ antibody comprises ~~an~~ a human IgG1 constant region and wherein said anti-TNF $\alpha$  antibody or antigen-binding fragment thereof (i) competitively inhibits binding of human TNF $\alpha$  to anti-TNF $\alpha$  chimeric monoclonal antibody cA2 which comprises the variable region of monoclonal antibody A2 (ATCC Accession No. PTA-7045) and (ii) binds to a neutralizing epitope of human TNF $\alpha$  *in vivo* with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant (K<sub>a</sub>), as determined by Scatchard analysis.
6. (Canceled)
7. (Currently Amended) A method of treating a TNF $\alpha$ -mediated ~~myelodysplastic syndrome~~ neoplastic disease in a human comprising administering to the human an effective TNF $\alpha$ -inhibiting amount of an anti-TNF $\alpha$  chimeric antibody, wherein said anti-TNF $\alpha$  chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
8. (Currently Amended) A method of treating a TNF $\alpha$ -mediated ~~myelodysplastic syndrome~~ neoplastic disease in a human comprising administering to the human an effective TNF $\alpha$ -inhibiting amount of an anti-TNF $\alpha$  chimeric antibody, wherein said anti-TNF $\alpha$  chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5 and an IgG1 human constant region.

9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.
11. (Canceled).
12. (Previously Presented) The method of Claim 1 wherein said anti-TNF $\alpha$  antibody is a humanized antibody.
13. (Previously Presented) The method of Claim 1 wherein said anti-TNF $\alpha$  antibody is a human antibody.
14. (Currently Amended) The method of Claim 1 wherein said anti-TNF $\alpha$  antibody ~~binds with high affinity to a neutralizing epitope of human TNF $\alpha$~~  is a chimeric antibody.
15. (Canceled).
16. (Previously Presented) The method of Claim 1 wherein said anti-TNF $\alpha$  antibody is administered to the human by means of parenteral administration.
17. (Previously Presented) The method of Claim 1 wherein said anti-TNF $\alpha$  antibody is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.
18. (Canceled).

19. (Previously Presented) The method of Claim 1 wherein said TNF $\alpha$ -inhibiting amount of said anti-TNF $\alpha$  antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.
20. (Previously Presented) The method of Claim 19 wherein the single or divided dose is selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.
21. (Canceled).
22. (New) The method of Claim 1, wherein said fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub> and Fv.